Epilepsy Surgery Market

Increasing prevalence and Use of Advanced Imaging Technology to propel market growth

Epilepsy is one of the most prevalent neurological illnesses worldwide, with an estimated 50 million individuals suffering from it, according to the WHO's fact sheets for 2019. People with epilepsy make up over 80% of the population in low- and middle-income nations. According to estimates, 70% of people with epilepsy might avoid seizures if their condition is adequately identified and treated. After a stroke, migraines, and Alzheimer's disease, epilepsy is the fourth most prevalent neurological condition. 

The US population's prevalence of active epilepsy was estimated at 1.2% (3.4 million) in 2015, according to the Centers for Disease Control and Prevention (CDC). At the University of Gondar Referral Hospital in Ethiopia, adult epileptic patients were evaluated in a research study published in 2018 on Sage Open Medicine. Seventy-nine adverse drug reactions were recorded, including exhaustion and gastrointestinal problems. Anticonvulsants, often antiepileptic medications, are a broad category of pharmaceuticals used to treat epileptic seizures.

Moreover, the growth in accidents and brain injuries, as well as the high rates of post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) incidence in patients with brain injuries, are the main factors propelling the epilepsy surgery industry. Thus, this factor is driving the Epilepsy Surgery market CAGR.

The epilepsy surgery market is being supported by the rising deployment of helper robots for precise and effective surgical planning & navigation. Due to much-reduced complication rates, better patient outcomes, and shorter operation times, patients choose minimally invasive epilepsy surgery. To treat epileptic diseases, epilepsy surgery involves stereo electroencephalography (SEEG), biopsy, thermal ablation of seizure foci or tumors, and deep brain stimulation (DBS). 

Additionally, computer-guided robotic arms derived from the automobile sector for neurosurgery applications were used before specialized stereotactic frameworks. To create a basic strategy for SEEG, neurologists and neurosurgeons work together under the direction of a noninvasive presurgical epilepsy workup. More than 150 recording locations may be available from a conventional montage of 10 electrodes. There have been few reports of robotic stereotactic aid in pediatric neurosurgery. Thus, it is anticipated that this aspect will accelerate the Epilepsy Surgery market revenue ly.

The Global Epilepsy Surgery Market Industry is poised for substantial growth, with projections indicating a market value of 1.24 USD Billion in 2024 and an anticipated increase to 2.3 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 5.79% from 2025 to 2035. Factors such as rising prevalence of epilepsy, advancements in surgical techniques, and increased healthcare investments are expected to drive this expansion. The market's evolution will likely be influenced by ongoing research and development efforts aimed at improving surgical outcomes and patient quality of life.

The increasing prevalence of epilepsy globally serves as a primary driver for the Global Epilepsy Surgery Market Industry. It is estimated that approximately 50 million individuals worldwide are affected by epilepsy, with a significant portion experiencing drug-resistant epilepsy. This condition often necessitates surgical intervention, thereby propelling market growth. The demand for surgical options is expected to rise as awareness of epilepsy and its treatment options increases. Consequently, the Global Epilepsy Surgery Market Industry is projected to reach 1.24 USD Billion in 2024, reflecting the urgent need for effective treatment alternatives.

Heightened awareness and educational initiatives regarding epilepsy and its treatment options are pivotal in driving the Global Epilepsy Surgery Market Industry. Campaigns aimed at educating both healthcare professionals and the general public about the condition and available surgical interventions have led to increased referrals for surgical evaluation. This growing awareness is likely to result in more patients seeking surgical options, thereby expanding the market. As knowledge about the benefits of epilepsy surgery spreads, the market is expected to witness sustained growth, aligning with the projected increase in market value over the next decade.

Regulatory support and the establishment of clinical guidelines for epilepsy surgery are essential drivers of the Global Epilepsy Surgery Market Industry. Organizations such as the American Epilepsy Society provide frameworks that promote best practices in surgical treatment. These guidelines not only enhance the credibility of surgical options but also encourage healthcare providers to consider surgery as a viable treatment pathway for drug-resistant epilepsy. As regulatory bodies continue to support surgical interventions, the market is likely to benefit from increased acceptance and utilization of epilepsy surgery, further contributing to its growth.

Innovations in surgical techniques and technologies are transforming the landscape of the Global Epilepsy Surgery Market Industry. Techniques such as laser interstitial thermal therapy and responsive neurostimulation have emerged, offering less invasive options with improved outcomes. These advancements not only enhance the safety and efficacy of epilepsy surgeries but also expand the patient population eligible for surgical intervention. As these technologies gain traction, they are likely to contribute to the market's growth trajectory, with projections indicating a market value of 2.3 USD Billion by 2035, driven by increased adoption of advanced surgical methods.

The expansion of healthcare infrastructure, particularly in developing regions, is a crucial factor influencing the Global Epilepsy Surgery Market Industry. Governments and private entities are increasingly investing in healthcare facilities and specialized epilepsy centers, which enhances access to surgical treatments. This investment is expected to facilitate early diagnosis and timely intervention, ultimately improving patient outcomes. As healthcare systems evolve, the demand for epilepsy surgeries is anticipated to rise, supporting a compound annual growth rate of 5.79% from 2025 to 2035, thereby reinforcing the market's growth potential.

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Epilepsy Surgery market accounted for USD 0.50 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Due to various elements, including the availability of well-established healthcare facilities, the high prevalence of neurological illnesses, and the rising incidence of epilepsy, the Americas dominated the epilepsy surgery market. The US. and Canada are the major countries of North America. 

A central nervous system (CNS) illness, which produces seizures and is the fourth most prevalent neurological disease, is believed to affect approximately 150,000 Americans. The incidence rate is also highest in small children under two and individuals aged 65 and over. Epilepsy is becoming more common in the Americas. Seizures afflict around 300,000 Canadians, and one in every 2,000 persons is diagnosed with epilepsy yearly. In the Canadian population, neurological illnesses are also among the top causes of disability.

Further, the major countries studied in the Epilepsy Surgery market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 EPILEPSY SURGERY MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

With increasing investment in research & development, the production of successful epilepsy medications, and a high prevalence of epilepsy, Europe Epilepsy Surgery market has also evolved as a prominent market for epilepsy surgery. The region has considerable growth potential that would help with the expansion of the epilepsy surgery market in the coming years. According to the 2020 EU Industrial Research & Development Scoreboard, companies in the European Union have increased their investment in research & development. In 2019, European companies invested 5.6% more in R&D, compared to 4.7% in 2018.

The production of successful medications to cure epilepsy in the region is increasing. Moreover, the UK Epilepsy Surgery market held the largest market share, and the Germany Epilepsy Surgery market was the fastest-growing market in the region.

The Asia-Pacific Epilepsy Surgery market offers lucrative opportunities for players, owing to a large senior population, governmental initiatives to improve the healthcare sector, increased research & development activities, and increased epilepsy incidence in the region. The prevalence of epilepsy in the elderly population is very high. It is estimated that the prevalence of epilepsy is 10.8 in 1,000. According to WHO, the population of the South-East Asia region is aging rapidly, and the proportion of people aged 60 or above was 9.7% in 2017.

It is also estimated that the geriatric population will increase to 13.7% and 20.3% by 2030 and by 2050, respectively. Further, the China Epilepsy Surgery market held the largest market share, and the India Epilepsy Surgery market was the fastest-growing market in the region.

Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Epilepsy Surgery. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming more and more competitive, Epilepsy Surgery industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business methods producers use in the  Epilepsy Surgery industry to benefit customers and increase the market sector. The Epilepsy Surgery industry has recently given medicine some of the most important advantages. In the Epilepsy Surgery market, major players such as Stryker (US), Zimmer Biomet Holdings Inc. (US), Auris Health Inc. (Hansen Medical Inc.) (US), Intuitive Surgical (US), Medtronic Plc (Mazor Robotics) (Ireland) In, Cephalon Inc (US), CMR Surgical (UK), Natus Medical Incorporated (US), Livanova Plc (UK), Monteris Medical (US) Company.

An American manufacturer of medical equipment is Medtronic plc. As a result of its acquisition of Covidien, an Irish corporation, the company has its operational and executive offices in Minneapolis, Minnesota, and its legal headquarters in Ireland. To treat medication-resistant epilepsy, Medtronic (Ireland) introduced its Deep Brain Stimulation system in the US in February 2019. For individuals with epilepsy who do not react to the medicine, the DBS offers a crucial surgical therapy alternative.

The da Vinci Surgical System is one of the robotic systems developed, produced, and marketed by Intuitive Surgical, Inc., an American company. These tools are intended to enhance clinical outcomes for patients through minimally invasive surgery. To create and distribute clinical video management and analytics tools for various surgical specialties, Intuitive Surgical (US) bought Orpheus Medical in February 2020. Intuitive Surgical can expand its integrated informatics platform thanks to this purchase.